Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal

The going rate to buy a voucher for a faster US FDA application review is about $100m, but the France-headquartered firm received considerably more from an unnamed big pharma.

queue
Ipsen sold the PRV received with the approval of Sohonos. • Source: Shutterstock

More from Rare Diseases

More from Pink Sheet